microRNA-125b在多种慢性肝病发生发展中的作用

卢能源; 王佳慧; 钟芳菲; 汪磊; 彭岳; 赵铁建; 郑洋

doi:10.3969/j.issn.1001-5256.2021.03.046

microRNA-125b在多种慢性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2021.03.046

1.
广西中医药大学赛恩斯新医药学院，南宁 530021
2.
广西中医药大学基础医学院生理教研室，南宁 530021

基金项目:

国家自然科学基金 (81660705);

国家自然科学基金 (81960751);

国家自然科学基金 (81960761);

广西自然基金 (2020JJB140144);

广西自然基金 (2020JJA140257);

广西中青年教师科研基础能力提升项目 (2020KY59009);

广西壮瑶药重点实验室 (GXZYZZ2019-1);

广西壮瑶药重点实验室 (GXZYZZ2020-07);

广西中医药大学一流学科 (2019XK141);

广西中医药大学赛恩斯新医药学院院级课题 (2019ZD03);

广西中医药大学校级课题青年基金 (2020QN006);

广西中医药大学赛恩斯新医药学院大学生创新创业训练项目(国家级) (202013643009);

广西中医药大学赛恩斯新医药学院大学生创新创业训练项目(国家级) (202013643014);

广西中医药大学赛恩斯新医药学院大学生创新创业训练项目(自治区级) (202013643027);

广西中医药大学赛恩斯新医药学院大学生创新创业训练项目(自治区级) (202013643032)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：卢能源负责文献检索, 文章思路设计, 论文撰写与修订；王佳慧、钟芳菲、汪磊、彭岳负责文献检索与资料分析；，赵铁建、郑洋负责指导撰写文章及最后定稿。

详细信息

作者简介:
卢能源(2000—)，男，主要从事民族药防治慢性肝病相关研究

通信作者:
郑洋，1793853705@qq.com

中图分类号: R575
计量
- 文章访问数: 484
- HTML全文浏览量: 101
- PDF下载量: 30
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-05
- 录用日期: 2020-10-30
- 出版日期: 2021-03-20

Role of microRNA-125b in the development and progression of various chronic liver diseases

1.
Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning 530021, China
2.
Department of Physiology, School of Basic Medical Sciences

摘要

摘要: 微小RNA(miRNA)是一类非编码的小分子RNA，是基因表达的转录后调控因子。简述了多种慢性肝病，包括代谢功能障碍相关性脂肪性肝病、慢性乙型肝炎、慢性丙型肝炎、慢性药物性肝损伤、肝硬化以及肝细胞癌的相关病因，归纳了近年来关于miR-125b通过靶向不同的靶基因，进入不同的信号转导途径而在同一肝病或病理进程中发挥着相同或相悖的调控作用的相关报道，以期为多种慢性肝病的发病机制研究和非创伤性鉴别手段的建立提供相关见解。
- 微RNAs /
- 肝疾病 /
- 基因表达调控
Abstract: MicroRNA (miRNA) is a type of small non-coding RNA and acts as a post-transcriptional regulator of gene expression. This article briefly describes the etiology of various chronic liver diseases, including metabolic dysfunction-associated fatty liver disease, chronic hepatitis B, chronic hepatitis C, chronic drug-induced liver injury, liver cirrhosis, and hepatocellular carcinoma, and summarizes related reports on microRNA-125b which enters different signal transduction pathways and plays the same or contradictory regulatory role in the same liver disease or pathological process by targeting different target genes, so as to provide insights into the research on the pathogenesis of various chronic liver diseases and the establishment of non-invasive differential methods.
- MicroRNAs /
- Liver Diseases /
- Gene Expression Regulation

HTML全文

参考文献(48)

[1]	ZHANG SL, PENG CJ, FENG ZJ, et al. Mechanism of action of microRNA in the regulation of hepatic ischemia－reperfusion injury[J]. J Clin Hepatol, 2019, 35(7): 1629-1631. DOI: 10.3969/j.issn.1001-5256.2019.07.045 张世龙, 彭慈军, 冯赞杰, 等. microRNA调控肝缺血再灌注损伤的作用机制[J]. 临床肝胆病杂志, 2019, 35(7): 1629-1631. DOI: 10.3969/j.issn.1001-5256.2019.07.045
[2]	JABANDZIEV P, BOHOSOVA J, PINKASOVA T, et al. The emerging role of noncoding rnas in pediatric inflammatory bowel disease[J]. Inflamm Bowel Dis, 2020, 26(7): 985-993. DOI: 10.1093/ibd/izaa009
[3]	SALIMINEJAD K, KHORRAM KHORSHID HR, SOLEYMANI FARD S, et al. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods[J]. J Cell Physiol, 2019, 234(5): 5451-5465. DOI: 10.1002/jcp.27486
[4]	MENS M, GHANBARI M. Cell cycle regulation of stem cells by microRNAs[J]. Stem Cell Rev Rep, 2018, 14(3): 309-322. DOI: 10.1007/s12015-018-9808-y
[5]	WANG JK, WANG Z, LI G. MicroRNA-125 in immunity and cancer[J]. Cancer Lett, 2019, 454: 134-145. DOI: 10.1016/j.canlet.2019.04.015
[6]	SUN YM, LIN KY, CHEN YQ. Diverse functions of miR-125 family in different cell contexts[J]. J Hematol Oncol, 2013, 6: 6. DOI: 10.1186/1756-8722-6-6
[7]	FOUAD Y, WAKED I, BOLLIPO S, et al. What's in a name? Renaming 'NAFLD' to 'MAFLD'[J]. Liver Int, 2020, 40(6): 1254-1261. DOI: 10.1111/liv.14478
[8]	ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312
[9]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039
[10]	ZHANG ZC, LIU Y, XIAO LL, et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice[J]. J Hepatol, 2015, 63(6): 1466-1475. DOI: 10.1016/j.jhep.2015.07.037
[11]	LI W, SUN Z, CHEN C, et al. Sirtuin7 has an oncogenic potential via promoting the growth of cholangiocarcinoma cells[J]. Biomed Pharmacother, 2018, 100: 257-266. DOI: 10.1016/j.biopha.2018.02.007
[12]	SHIN J, HE M, LIU Y, et al. SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease[J]. Cell Rep, 2013, 5(3): 654-665. DOI: 10.1016/j.celrep.2013.10.007
[13]	LANINI S, USTIANOWSKI A, PISAPIA R, et al. Viral hepatitis: Etiology, epidemiology, transmission, diagnostics, treatment, and prevention[J]. Infect Dis Clin North Am, 2019, 33(4): 1045-1062. DOI: 10.1016/j.idc.2019.08.004
[14]	INOUE T, TANAKA Y. The role of hepatitis B core-related antigen[J]. Genes (Basel), 2019, 10(5): 357. DOI: 10.3390/genes10050357
[15]	TAO YC, WANG ML, WANG M, et al. Quantification of circulating miR-125b-5p predicts survival in chronic hepatitis B patients with acute-on-chronic liver failure[J]. Dig Liver Dis, 2019, 51(3): 412-418. DOI: 10.1016/j.dld.2018.08.030
[16]	DENG W, ZHANG X, MA Z, et al. MicroRNA-125b-5p mediates post-transcriptional regulation of hepatitis B virus replication via the LIN28B/let-7 axis[J]. RNA Biol, 2017, 14(10): 1389-1398. DOI: 10.1080/15476286.2017.1293770
[17]	ZHANG Z, CHEN J, HE Y, et al. miR-125b inhibits hepatitis B virus expression in vitro through targeting of the SCNN1A gene[J]. Arch Virol, 2014, 159(12): 3335-3343. DOI: 10.1007/s00705-014-2208-y
[18]	SPEARMAN CW, DUSHEIKO GM, HELLARD M, et al. Hepatitis C[J]. Lancet (London, England), 2019, 394(10207): 1451-1466. DOI: 10.1016/S0140-6736(19)32320-7
[19]	ELEMEERY MN, BADR AN, MOHAMED MA, et al. Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients[J]. World J Gastroenterol, 2017, 23(21): 3864-3875. DOI: 10.3748/wjg.v23.i21.3864
[20]	SHWETHA S, SHARMA G, RAHEJA H, et al. Interaction of miR-125b-5p with Human antigen R mRNA: Mechanism of controlling HCV replication[J]. Virus Res, 2018, 258: 1-8. DOI: 10.1016/j.virusres.2018.09.006
[21]	SHWETHA S, KUMAR A, MULLICK R, et al. HuR displaces polypyrimidine tract binding protein to facilitate La binding to the 3' untranslated region and enhances hepatitis C virus replication[J]. J Virol, 2015, 89(22): 11356-11371. DOI: 10.1128/JVI.01714-15
[22]	DAI CY, TSAI YS, CHOU WW, et al. The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection[J]. Oncotarget, 2018, 9(13): 11291-11302. DOI: 10.18632/oncotarget.24129
[23]	YE H, NELSON LJ, GÓMEZ DEL MORAL M, et al. Dissecting the molecular pathophysiology of drug-induced liver injury[J]. World J Gastroenterol, 2018, 24(13): 1373-1385. DOI: 10.3748/wjg.v24.i13.1373
[24]	CHEN C, LIU YH, CHENG SB, et al. The hepatoprotective effects of XCHD and MgIG against methotrexate-induced liver injury and inflammation in rats through suppressing the activation of AIM2 inflammasomes[J]. Pathol Res Pract, 2020, 216(4): 152875. DOI: 10.1016/j.prp.2020.152875
[25]	YE JH, HO YF, ON AW, et al. Trends in reporting drug-associated liver injuries in Taiwan: A focus on amiodarone[J]. Int J Clin Pharm, 2018, 40(4): 911-920. DOI: 10.1007/s11096-018-0698-5
[26]	WANG C, HUANG W, LIN J, et al. Triclosan-induced liver and brain injury in zebrafish (Danio rerio) via abnormal expression of miR-125 regulated by PKCα/Nrf2/p53 signaling pathways[J]. Chemosphere, 2020, 241: 125086. DOI: 10.1016/j.chemosphere.2019.125086
[27]	LI Y, REN Q, ZHU L, et al. Involvement of methylation of MicroRNA-122, -125b and -106b in regulation of Cyclin G1, CAT-1 and STAT3 target genes in isoniazid-induced liver injury[J]. BMC Pharmacol Toxicol, 2018, 19(1): 11. DOI: 10.1186/s40360-018-0201-x
[28]	AYD_IN MM, AKÇAL_I KC. Liver fibrosis[J]. Turk J Gastroenterol, 2018, 29(1): 14-21.
[29]	SMITH A, BAUMGARTNER K, BOSITIS C. Cirrhosis: Diagnosis and management[J]. Am Fam Physician, 2019, 100(12): 759-770.
[30]	CHEN Z, JAIN A, LIU H, et al. Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis[J]. J Pharmacol Exp Ther, 2019, 370(3): 695-702. DOI: 10.1124/jpet.118.256156
[31]	CAI Q, CHEN F, XU F, et al. Epigenetic silencing of microRNA-125b-5p promotes liver fibrosis in nonalcoholic fatty liver disease via integrin α8-mediated activation of RhoA signaling pathway[J]. Metabolism, 2020, 104: 154140. DOI: 10.1016/j.metabol.2020.154140
[32]	YOU K, LI SY, GONG J, et al. MicroRNA-125b promotes hepatic stellate cell activation and liver fibrosis by activating RhoA signaling[J]. Mol Ther Nucleic Acids, 2018, 12: 57-66. DOI: 10.1016/j.omtn.2018.04.016
[33]	RINGELHAN M, PFISTER D, O'CONNOR T, et al. The immunology of hepatocellular carcinoma[J]. Nat Immunol, 2018, 19(3): 222-232. DOI: 10.1038/s41590-018-0044-z
[34]	XU J, AN P, WINKLER CA, et al. Dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma: Potential as biomarkers and therapeutic targets[J]. Front Oncol, 2020, 10: 1271. DOI: 10.3389/fonc.2020.01271
[35]	WANG JK, WANG Z, LI G. MicroRNA-125 in immunity and cancer[J]. Cancer Lett, 2019, 454: 134-145. DOI: 10.1016/j.canlet.2019.04.015
[36]	FRITSCH R, HOEPPNER J. Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 285-291. DOI: 10.1080/17474124.2019.1573143
[37]	ABDELGALIL AA, ALKAHTANI HM, AL-JENOOBI FI. Sorafenib[J]. Profiles Drug Subst Excip Relat Methodol, 2019, 44: 239-266.
[38]	CHANG QQ, PENG Y, WANG GJ, et al. Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents[J]. Chin J Clin Pharmacol Ther, 2019, 24(8): 948-956. 常青青, 彭英, 王广基, 等. 抗肝癌小分子酪氨酸激酶抑制剂的临床研究进展[J]. 中国临床药理学与治疗学, 2019, 24(8): 948-956.
[39]	REN WW, LI DD, CHEN X, et al. MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy[J]. Cell Death Dis, 2018, 9(5): 547. DOI: 10.1038/s41419-018-0592-z
[40]	HU J, ZHANG J, SUN F, et al. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor[J]. Anticancer Drugs, 2019, 30(7): e0746. http://www.ncbi.nlm.nih.gov/pubmed/31305292
[41]	LI J, FANG L, YU W, et al. MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif[J]. Oncol Lett, 2015, 9(4): 1971-1975. DOI: 10.3892/ol.2015.2973
[42]	ZHOU W, WENG J, WU K, et al. Silencing of TAZ inhibits the motility of hepatocellular carcinoma cells through autophagy induction[J]. Cancer Manag Res, 2019, 11: 8743-8753. DOI: 10.2147/CMAR.S215466
[43]	QIANG L, HE YY. Autophagy deficiency stabilizes TWIST1 to promote epithelial-mesenchymal transition[J]. Autophagy, 2014, 10(10): 1864-1865. DOI: 10.4161/auto.32171
[44]	HUA S, QUAN Y, ZHAN M, et al. miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1[J]. Cancer Cell Int, 2019, 19: 203. DOI: 10.1186/s12935-019-0919-6
[45]	LEE D, XU IM, CHIU DK, et al. Induction of oxidative stress through inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma[J]. Hepatology, 2019, 69(4): 1768-1786. DOI: 10.1002/hep.30467
[46]	SONG S, YANG Y, LIU M, et al. MiR-125b attenuates human hepatocellular carcinoma malignancy through targeting SIRT6[J]. Am J Cancer Res, 2018, 8(6): 993-1007. http://europepmc.org/articles/PMC6048406/?report=classic
[47]	KIM JK, NOH JH, JUNG KH, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b[J]. Hepatology, 2013, 57(3): 1055-1067. DOI: 10.1002/hep.26101
[48]	ZHANG Y, LI H, CHANG H, et al. MTP18 overexpression contributes to tumor growth and metastasis and associates with poor survival in hepatocellular carcinoma[J]. Cell Death Dis, 2018, 9(10): 956. DOI: 10.1038/s41419-018-0987-x